undamentalytics Newsletter
Sign in

PTC Therapeutics, Inc. (PTCT) stock

Add to watchlist

Add holding +

NASDAQ: PTCT Nasdaq Biotechnology Next results ~January 18, 2027

B Fundamentals grade

PTC Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$40

Cash-flow model

Base case. Range ~$35–$47 across our lower- and higher-growth cases (-1%–9% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 34% below it.

Price used: $60.88, November 2, 2026

PTC Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 13 selling0 purchases and 203 sales by directors and officers, last 12 monthsInsider trades
  • Funds213 adding, 157 cuttingOf 61 active managers that changed their stake, 30 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter PTC Therapeutics files

10-Q filed October 29: PTC Therapeutics

Model value +8.6%

PTC Therapeutics reported revenue of $1.16bn for the twelve months to September 2026, down 35.1% on a year earlier. That marks a smaller decline than the 42.8% drop recorded a quarter earlier. Profitability has weakened sharply: free-cash-flow margin fell to 0.2% from 39.6%, while operating margin narrowed to 12.8% from 43.6%. Existing holders face further dilution, with the diluted share count up 9.3% on a year earlier. Despite the softer margins, the fundamentals grade has improved, moving from C to B. Our model value has also risen, from $33.84 to $36.74 a share, though this remains well below the current share price of $64.16. The rating stays Sell.

Source: 10-Q filed October 29, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where PTC Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.01bn, down 42.8% on a year earlier, a smaller fall than the 53.3% decline a quarter earlier. That puts it 20 of 21 for growth among the biotechnology companies we cover. Free-cash-flow margin fell to -3.9% from 39.5% a year earlier. Operating margin narrowed to 12.5% from 40.7%. The diluted share count is up 14.0% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 5 financial-health checks. Our cash-flow model value is $33.84 a share, against a share price of $60.75.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 18, 2027 (estimated)

PTC Therapeutics, Inc.'s trailing-twelve-month revenue fell 35.1% year on year, with a free-cash-flow margin of 0.2%. Where it stands out: operating margin of 12.8% ranks 28 of 175 biotechnology companies we cover.

Our discounted-cash-flow model values the business at ~$40 per share in the base case (~$35–$47 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth accelerating: TTM revenue growth rose to -35.1% (+7.8pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in PTC Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Priced above our value. The share price of $60.88 is 34% above our value per share of $40.
  • Revenue shrinking. Revenue fell 35.1% over the last 12 months.
  • Margins narrowing. Operating margin is down 30.8 points on a year ago.
  • Share dilution. Diluted shares rose 9.3% in a year.
  • Insiders selling. 13 insiders sold $57M of stock over the past 365 days and none bought (100% under pre-set trading plans).
  • Heavily shorted. 13.5% of the shares available to trade are sold short (6.4 days of average volume to cover).

Latest results: FY2026 Q3

Filed October 29, 2026
Earnings per share
-$0.39 against an average estimate of $0.27: missed by 243.9%
Revenue
$358m, up 69.6% on a year earlier
Share reaction
-4.8% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Next report
October 29, 2026; average EPS estimate $0.14

PTC Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.5%
  • 1 week-0.3%
  • 1 month-4.1%
  • This year-19.9%
  • 1 year-10.9%
  • 5 years+49.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.2B
Operating margin
12.8%
Net margin
-9.2%
EPS (TTM, diluted)
$-1.18

Growth

Revenue growth
−35.1%
Change in growth rate
+7.8 pts
Share count change
+9.3%

Cash

Free cash flow (TTM)
$2.1M
FCF margin
0.2%
Stock pay % of revenue
7.7%

Earnings

Last results
October 29, 2026
Next results (est.)
January 18, 2027

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Buyback
  2. Announcement
  3. Results
  4. Announcement
  5. Announcement
  6. Announcement
  7. Agreement
  8. Announcement
  9. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

PTC Therapeutics, Inc. valuation models and calculator

What the price is pricing in

The share price implies about 19.7% a year of cash-flow growth for five years.That is close to the 16.5% a year revenue growth PTC Therapeutics has delivered.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in19.7%
  • Last 12 months-35.1%
  • 3 years a year13.1%
  • 5 years a year16.5%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($64.87, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$40
Price used
$64.87close November 3, 2026
Implied change
▼ 38%
Uncertainty
Low

How we got here: a discounted-cash-flow model of PTC Therapeutics, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($85.8M, FY2026 Q3 TTM), growing 13.2% and 4.9% in the next two years (forecasts, guidance and its record), then back to 4% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$35–~$47 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of PTC Therapeutics, Inc.'s free cash flow after stock-based pay ( $85.8M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value PTC Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$40 ~$35–$47 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$40 ~$35–$47 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare PTC Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −1%
  • Revenue growth 5 points higher ▲ +1%
  • Last year's free-cash-flow margin change, if it persists ▼ −82%
  • Discount rate 1 point higher ▼ −0%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $34$39$46$55$68$83
8.5% $30$34$39$46$55$66
10% $28$31$35$40$47$55

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$32.40$10.91$16.68$34.32$48.03$61.03$39.83$38.17$27.56$45.14$75.96$60.88
Market value$1.1bn$371m$654m$1.6bn$2.8bn$4.0bn$2.8bn$2.7bn$2.1bn$3.5bn$6.7bn$5.5bn
+ Net debt (− = net cash)$34m$40m$33m−$16m$26m$100m$242m$292m−$310m−$494m−$412m$27m
Enterprise value$1.1bn$411m$687m$1.6bn$2.9bn$4.1bn$3.0bn$3.0bn$1.8bn$3.0bn$6.3bn$5.5bn
Multiples
Price / sales 29.6x4.5x3.4x6.0x9.2x10.6x5.2x3.9x2.2x4.3x3.9x4.7x
Price / earnings ——————————9.8x—
Price / free cash flow ——————————9.6xn/m
EV / EBITDA ——————————7.0x26.4x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

11 /100

Weak moat

How hard PTC Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -21.5% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -57.4%; its worst year was -113.9%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 3 of 10 years, at a median -32.6% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 28.4% over five years; stock-based pay has been a median 13.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (16 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.52 −80% $1.3bn −24%
Next $2.43 +59% $1.4bn +9%

Next year's EPS estimate has moved −2.8% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −4.5% on 90 days ago. In the last 30 days, 1 analyst raised PTC Therapeutics, Inc.'s forecast and 1 cut it.

Consensus EPS forecast PTC Therapeutics, Inc., last 90 days
$1.50 $2.00 $2.50 $3.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.60 Current fiscal year, 60 days ago: $1.60 Current fiscal year, 30 days ago: $1.71 Current fiscal year, 7 days ago: $1.52 Current fiscal year, Now: $1.52 $1.52 Next fiscal year, 90 days ago: $2.50 Next fiscal year, 60 days ago: $2.50 Next fiscal year, 30 days ago: $2.68 Next fiscal year, 7 days ago: $2.37 Next fiscal year, Now: $2.43 $2.43

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.60$2.50
60 days ago $1.60$2.50
30 days ago $1.71$2.68
7 days ago $1.52$2.37
Now $1.52$2.43

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.27 −$0.39 −243.9%
Jun 2026 $0.34 $0.92 +170.6%
Mar 2026 −$0.44 −$0.03 +93.2%
Dec 2025 −$0.41 −$1.80 −343.5%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows PTC Therapeutics, Inc.'s revenue by +13.2% next year and +4.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+20.5%, weight 56%) and the company's own record (+4.0%, weight 44%) . How the weights are set.

Analyst recommendations

15 analysts, Oct 2026
Buy1280%
Hold213%
Sell17%

Monthly trend

  1. Oct 202648215
  2. Sep 2026481114
  3. Aug 2026472114
  4. Jul 2026472114

Counts of recommendations published by analysts covering PTC Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.5%
of tradable shares
Days to cover
6.38
at average volume
Short interest, 1 month
−15%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
7.3%
of shares
Employees
991
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −10.9%

$68.31 on October 31, 2025 to $60.88

ThenNowEffect
Revenue (last 12 months) $1.8bn $1.0bn −42.8%
P/S multiple 3.1x 5.5x +77.7%
Share count 80m 91m −12.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +211.7%

$19.53 on November 3, 2023 to $60.88

ThenNowEffect
Revenue (last 12 months) $819m $1.0bn +23.2%
P/S multiple 1.7x 5.5x +213.9%
Share count 73m 91m −19.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PTCT−35%−4%−28%+64%+68%−20%
Industry peers (median)−36%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PTCT33%58%42%83%58%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PTCT−49%−43%−69%−24%−37%−34%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 88% from November 18, 2015 to November 3, 2016. Getting back needed a 728% gain, reached on June 1, 2018, 575 days after the low.

Price behaviour

52-week range
$59.24 – $89.55
From 52-week high
−32.0%
vs 50-day average
−6.6%
vs 200-day average
−13.8%
Volatility (1 year)
41%
Beta vs S&P 500
0.78

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±5.4%
After a week
6 up, 5 down
typical move ±5.6%
After a month
7 up, 4 down
typical move ±10.0%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 −4.8% −2.1% — —
July 30, 2026 −8.7% +2.4% −4.9% −5.9%
May 7, 2026 +10.7% +0.5% +9.2% +6.5%
February 19, 2026 +2.5% +0.5% −1.2% −5.3%
January 12, 2026 −2.7% 0.0% −5.8% −8.5%
November 4, 2025 +5.7% −0.8% +8.7% +14.6%
August 7, 2025 −11.6% +0.7% −5.2% +10.9%
May 6, 2025 +0.3% −0.4% +14.1% +27.3%
February 27, 2025 +8.4% −0.1% +3.6% +6.4%
January 13, 2025 −4.8% +0.3% +3.0% +11.4%
November 7, 2024 +2.5% +1.2% −1.9% +11.3%
August 8, 2024 −1.8% +2.8% +3.7% −1.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How PTC Therapeutics, Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

PTC Therapeutics, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) PTC Therapeutics, Inc.
$500M $1B $1.5B $2B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $937.8M Revenue (TTM), FY24 Q1: $927.6M Revenue (TTM), FY24 Q2: $900.5M Revenue (TTM), FY24 Q3: $900.7M Revenue (TTM), FY24 Q4: $806.8M Revenue (TTM), FY25 Q1: $1.8B Revenue (TTM), FY25 Q2: $1.8B Revenue (TTM), FY25 Q3: $1.8B Revenue (TTM), FY25 Q4: $1.7B Revenue (TTM), FY26 Q1: $827.1M Revenue (TTM), FY26 Q2: $1B Revenue (TTM), FY26 Q3: $1.2B $1.2B

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $937.8M
FY24 Q1 $927.6M
FY24 Q2 $900.5M
FY24 Q3 $900.7M
FY24 Q4 $806.8M
FY25 Q1 $1.8B
FY25 Q2 $1.8B
FY25 Q3 $1.8B
FY25 Q4 $1.7B
FY26 Q1 $827.1M
FY26 Q2 $1B
FY26 Q3 $1.2B
Revenue growth, TTM YoY PTC Therapeutics, Inc.
-100% -50% 0% 50% 100% 150% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 34.2% Revenue growth, TTM YoY, FY24 Q1: 20.4% Revenue growth, TTM YoY, FY24 Q2: 10.0% Revenue growth, TTM YoY, FY24 Q3: 12.8% Revenue growth, TTM YoY, FY24 Q4: -14.0% Revenue growth, TTM YoY, FY25 Q1: 91.1% Revenue growth, TTM YoY, FY25 Q2: 96.0% Revenue growth, TTM YoY, FY25 Q3: 97.5% Revenue growth, TTM YoY, FY25 Q4: 114.5% Revenue growth, TTM YoY, FY26 Q1: -53.3% Revenue growth, TTM YoY, FY26 Q2: -42.8% Revenue growth, TTM YoY, FY26 Q3: -35.1% -35.1%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 34.2%
FY24 Q1 20.4%
FY24 Q2 10.0%
FY24 Q3 12.8%
FY24 Q4 -14.0%
FY25 Q1 91.1%
FY25 Q2 96.0%
FY25 Q3 97.5%
FY25 Q4 114.5%
FY26 Q1 -53.3%
FY26 Q2 -42.8%
FY26 Q3 -35.1%
Operating margin (TTM) PTC Therapeutics, Inc.
-50% 0% 50% 100% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -46.9% Operating margin (TTM), FY24 Q1: -39.6% Operating margin (TTM), FY24 Q2: -22.0% Operating margin (TTM), FY24 Q3: -14.9% Operating margin (TTM), FY24 Q4: -37.5% Operating margin (TTM), FY25 Q1: 40.2% Operating margin (TTM), FY25 Q2: 40.7% Operating margin (TTM), FY25 Q3: 43.6% Operating margin (TTM), FY25 Q4: 50.1% Operating margin (TTM), FY26 Q1: -7.1% Operating margin (TTM), FY26 Q2: 12.5% Operating margin (TTM), FY26 Q3: 12.8% 12.8%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -46.9%
FY24 Q1 -39.6%
FY24 Q2 -22.0%
FY24 Q3 -14.9%
FY24 Q4 -37.5%
FY25 Q1 40.2%
FY25 Q2 40.7%
FY25 Q3 43.6%
FY25 Q4 50.1%
FY26 Q1 -7.1%
FY26 Q2 12.5%
FY26 Q3 12.8%
FCF margin (TTM) PTC Therapeutics, Inc.
-40% -20% 0% 20% 40% 60% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -19.9% FCF margin (TTM), FY24 Q1: -9.3% FCF margin (TTM), FY24 Q2: -14.4% FCF margin (TTM), FY24 Q3: -20.7% FCF margin (TTM), FY24 Q4: -14.2% FCF margin (TTM), FY25 Q1: 39.1% FCF margin (TTM), FY25 Q2: 39.5% FCF margin (TTM), FY25 Q3: 39.6% FCF margin (TTM), FY25 Q4: 40.6% FCF margin (TTM), FY26 Q1: -27.4% FCF margin (TTM), FY26 Q2: -3.9% FCF margin (TTM), FY26 Q3: 0.2% 0.2%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -19.9%
FY24 Q1 -9.3%
FY24 Q2 -14.4%
FY24 Q3 -20.7%
FY24 Q4 -14.2%
FY25 Q1 39.1%
FY25 Q2 39.5%
FY25 Q3 39.6%
FY25 Q4 40.6%
FY26 Q1 -27.4%
FY26 Q2 -3.9%
FY26 Q3 0.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar PTC Therapeutics took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $1.7B
  2. Research and development $455M · 26.3%
  3. Selling, general and admin $347M · 20.1%
  4. Other operating costs $61.3M · 3.5%
  5. Operating income $867M · 50.1%
  6. Income tax $14M · 0.8%
  7. Interest and other $170M · 9.8%
  8. Net income $683M · 39.4%

Shares of revenue. Source: PTC Therapeutics's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 105 34 35 25 37 83 194 265 307 381 539 699 938 807 1,731 1,156
Gross profit — — — — — — 190 252 295 — — — — — — —
EBITDA 33 −24 −43 −97 −164 −129 −47 −90 −209 −388 −310 −319 −203 −227 906 209
Operating income 31 −27 −45 −99 −167 −132 −64 −116 −241 −432 −374 −447 −440 −303 867 148
Net income 31 −26 −52 −94 −170 −142 −79 −128 −252 −438 −524 −559 −627 −363 683 −106
Diluted EPS $4.55 $42.50 −$5.18 −$2.97 −$5.07 −$4.17 −$2.02 −$2.75 −$4.27 −$6.64 −$7.43 −$7.79 −$8.37 −$4.73 $7.78 −$1.18
Growth (year on year)
Revenue — −67.8% +2.2% −27.2% +45.6% +124.9% +135.0% +36.2% +16.0% +24.0% +41.4% +29.7% +34.2% −14.0% +114.5% −35.1%
EBITDA — −172.1% — — — — — — — — — — — — — −74.2%
Operating income — −187.7% — — — — — — — — — — — — — −81.0%
Net income — −184.9% — — — — — — — — — — — — — −114.1%
Diluted EPS — +834.1% — — — — — — — — — — — — — −112.9%
Margins
Gross margin — — — — — — 97.6% 95.2% 96.0% — — — — — — —
EBITDA margin 31.7% −71.0% −123.9% −384.9% −446.8% −155.7% −24.0% −33.8% −68.1% −102.0% −57.6% −45.6% −21.6% −28.1% 52.3% 18.1%
Operating margin 29.0% −79.0% −130.8% −393.8% −454.6% −159.7% −33.1% −43.7% −78.6% −113.4% −69.5% −64.0% −46.9% −37.5% 50.1% 12.8%
Net margin 29.3% −77.3% −148.6% −371.4% −463.6% −171.8% −40.6% −48.4% −82.0% −115.1% −97.3% −80.0% −66.8% −45.0% 39.4% −9.2%
Free-cash-flow margin −19.9% −141.7% −137.7% −245.3% −345.6% −127.4% −6.8% −13.1% −36.6% −55.7% −51.9% −55.6% −19.9% −14.2% 40.6% 0.2%
Cash flow
Cash from operations −21 −48 −47 −57 −124 −104 −10 −28 −99 −194 −251 −357 −158 −108 711 10
Capital spending 0 0 1 5 3 2 3 7 14 18 28 32 28 7 9 8
Free cash flow −21 −48 −48 −62 −127 −105 −13 −35 −112 −212 −280 −389 −187 −114 702 2
Stock-based pay 3 2 8 19 34 35 31 33 42 70 104 110 102 75 75 89
Free cash flow after stock pay −24 −50 −56 −81 −161 −140 −44 −68 −155 −282 −383 −499 −288 −189 628 −87
Balance sheet
Cash 28 3 15 50 58 58 112 169 288 209 190 280 594 780 985 509
Total debt 0 5 — 0 92 98 145 153 314 309 431 572 284 285 573 536
Net debt (negative = net cash) −28 2 −15 −50 34 40 33 −16 26 100 242 292 −310 −494 −412 27
Diluted shares — 17m 13m 32m 34m 34m 39m 47m 59m 66m 70m 72m 75m 77m 88m 90m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 4 checks passed · September 30, 2026
What it owns · $3.2bn
Short-term assets $2.5bnLonger-term assets $670m
What it owes, and who funded it · $3.4bn
Short-term liabilities $776mLonger-term liabilities $2.6bnShareholders' equity $-191m
  • Short-term assets cover short-term liabilities $2.5bn of assets due within a year against $776m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $2.5bn short-term assets against $2.6bn of longer-dated liabilities.
  • More cash than debt $509m of cash against $536m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $10m of operating cash flow against $536m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From PTC Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+9.3%
year over year
R&D spending
37.9%
of revenue
Sales & admin spending
29.7%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated PTCT ACAD LKFT MDGL LEGN KNSA Median
Revenue, last 12 months $1.2bn $1.1bn $1.3bn $1.3bn $1.0bn $946m $56m
Revenue growth, last 12 months −35.1% 11.8% 321.6% 149.0% 64.0% 58.2% 12.6%
Revenue growth, 3-year average 13.1% 27.4% — — — 56.1% 13.7%
Revenue growth, latest quarter 69.6% 16.4% — 71.2% — 58.1% 10.2%
Gross margin 96.0% 91.1% 97.3% — 61.4% 90.2% 82.9%
Operating margin 12.8% 7.6% 26.5% −25.1% −13.3% 13.8% −189.4%
Operating margin, 3-year average 13.8% 11.1% −39.1% <−999% — 4.4% −363.5%
Net margin −9.2% 33.4% 28.9% −25.3% −28.8% 11.6% −169.8%
Cash from operations / revenue 0.9% 14.1% −23.1% −15.4% −9.7% 21.0% −168.0%
Free-cash-flow margin 0.2% 12.8% −24.4% −16.1% −12.5% 20.8% −162.4%
Free-cash-flow margin, 3-year average 6.4% 0.8% −127.4% <−999% — 13.6% −310.0%
Stock pay / revenue 7.7% 5.1% 2.2% 9.5% — 4.8% 20.0%
Change in share count 9.3% 3.0% 0.0% 14.8% 0.8% 8.5% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -35.1% 12.6% 135 of 172
Change in growth rate Growth +7.8pp -0.1pp 49 of 172
Operating margin Profitability 12.8% -189.4% 28 of 175
Net margin Profitability -9.2% -157.3% 45 of 180
Free-cash-flow margin Cash generation 0.2% -145.4% 42 of 176
Stock pay as % of revenue Cash generation 7.7% 19.2% 47 of 179
Long-term debt as % of assets Balance sheet 16.7% 20.6% 35 of 78
Change in share count Balance sheet 9.3% 7.9% 87 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Collaboration and License Revenue $998M ▲ 328306.9%
Products $587M ▲ 0.8%
Royalty $244M ▲ 19.8%
Translarna1 $235M ▼ 26.7%
Emflaza $146M ▼ 29.4%
Sephience $111M —
Upstaza and Kebilidi $56.6M ▲ 234.8%
Other Products $37.3M ▲ 0.9%
Translarna -$98.6M ▼ 624.5%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue YoY
United States $252M ▲ 21.7%
Outside the US $236M ▼ 40.1%
All Other Countries Other Than Russia Brazil and United States $168M ▼ 14.7%
RU $100M ▼ 4.7%
Brazil $65.7M ▼ 8.9%

These categories overlap or exclude eliminations, so shares aren't shown.

From PTC Therapeutics, Inc.'s 10-K filed February 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$8.2B
Institutions reporting
380
Shares held vs prior quarter
▲ 5.0%
Positions opened / closed
71 / 44

Top buyers and sellers, Q2 2026: 213 institutions bought and 157 sold ; the biggest buyer was Westfield Capital Management Co LP (+2.0M shares) and the biggest seller UBS Group AG (−1.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $1.1B 14.0M 13.9% ▲ 7.8%
RTW Investments, LP $632M 7.7M 7.7% 0.0%
Jupiter Topco LLC $590M 7.2M 7.2% —
Vanguard Portfolio Management LLC $402M 4.9M 4.9% ▲ 2.6%
State Street Corp $375M 4.6M 4.6% ▲ 5.8%
Wellington Management Group LLP $337M 4.1M 4.1% ▲ 4.7%
Vanguard Capital Management LLC $305M 3.7M 3.7% ▲ 1.7%
Geode Capital Management, LLC $180M 2.2M 2.2% ▼ 0.1%
Toronto Dominion Bank $177M 2.2M 2.2% ▼ 28.4%
Westfield Capital Management Co LP $160M 2.0M 2.0% New
Hood River Capital Management LLC $142M 1.7M 1.7% ▲ 4.4%
William Blair Investment Management, LLC $141M 1.7M 1.7% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not PTC Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $56.8M 203 trades by 13 insiders · 100% under pre-set plans
Net ▼ $56.8M net selling
Insider Date Trade Shares Price Value
Schmertzler Michael Director October 14, 2026 Sell pre-set plan 382 $60.14 $22,973
Schmertzler Michael Director October 14, 2026 Sell pre-set plan 2,118 $59.52 $126,063
Boulding Mark Elliott EXEC. VP AND CLO October 9, 2026 Sell pre-set plan 192 $64.26 $12,338
Schmertzler Michael Director October 7, 2026 Sell pre-set plan 53 $63.95 $3,389
Schmertzler Michael Director October 7, 2026 Sell pre-set plan 2,447 $63.38 $155,091
Boulding Mark Elliott EXEC. VP AND CLO October 6, 2026 Sell pre-set plan 435 $64.16 $27,910
Boulding Mark Elliott EXEC. VP AND CLO October 5, 2026 Sell pre-set plan 1,638 $64.03 $104,881
Steele Glenn Jr Md Phd Director September 30, 2026 Sell pre-set plan 12,000 $65.16 $781,920
Schmertzler Michael Director September 17, 2026 Sell pre-set plan 9,624 $67.83 $652,796
Schmertzler Michael Director September 17, 2026 Sell pre-set plan 376 $68.45 $25,737
Schmertzler Michael Director September 16, 2026 Sell pre-set plan 7,006 $67.35 $471,854
Schmertzler Michael Director September 16, 2026 Sell pre-set plan 2,994 $66.58 $199,341

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 18, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • July 30, 2026
  • May 7, 2026
  • February 19, 2026
  • January 12, 2026
  • November 4, 2025

Recent SEC filings

Data status

When each part of this page on PTC Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

PTC Therapeutics, Inc. in brief

What does PTC Therapeutics, Inc. do?
PTC Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is PTC Therapeutics, Inc.'s stock ticker?
PTC Therapeutics, Inc. trades under the ticker PTCT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is PTC Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, PTC Therapeutics, Inc. reported revenue of $1.2B, 35.1% lower than a year earlier, according to its SEC filings.
What is PTC Therapeutics, Inc.'s free cash flow?
PTC Therapeutics, Inc.'s free-cash-flow margin is 0.2% of revenue over the trailing twelve months, ranking 42 of the 176 biotechnology companies we cover.
What is PTC Therapeutics, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of PTC Therapeutics, Inc.'s free cash flow after stock-based pay gives ~$40 per share in the base case, and ~$35–$47 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are PTC Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., RTW Investments, LP and Jupiter Topco LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is PTC Therapeutics, Inc.'s market cap?
On November 2, 2026, PTC Therapeutics, Inc.'s market capitalisation was about $5.5B and net debt of $27.4M. Market figures come from third-party market data and may be delayed.
Who are PTC Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to PTC Therapeutics, Inc. are Acadia Pharmaceuticals Inc, Lakefront Biotherapeutics NV, Madrigal Pharmaceuticals, Inc., Legend Biotech Corp and Kiniksa Pharmaceuticals International, plc. The side-by-side comparison below sets their revenue, margins and growth against PTC Therapeutics, Inc.'s.
Are insiders buying or selling PTC Therapeutics, Inc. stock?
Over the last 12 months, PTC Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 203 sales on Form 4. The insider trading page charts every trade.
When is PTC Therapeutics, Inc.'s next earnings date?
Around January 18, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — PTC Therapeutics, Inc. announces its own schedule.